2-Methoxy-5-(trifluoromethyl)aniline | CAS:349-65-5

We serve 2-Methoxy-5-(trifluoromethyl)aniline CAS:349-65-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Methoxy-5-(trifluoromethyl)aniline

Chemical Name:2-Methoxy-5-(trifluoromethyl)aniline
CAS.NO:349-65-5
Synonyms:2-Methoxy-5-(trifluoromethyl)aniline
2-amino-4-trifluoromethylanisole
2-Amino-4-(trifluoromethyl)anisole
2-methoxy-5-trifluoromethyl-aniline
3-Amino-4-methoxybenzotrifluoride
Molecular Formula:C8H8F3NO
Molecular Weight:191.15000
 
Physical and Chemical Properties:
Density:1.28
Melting point:58-60ºC
Boiling point:230.1ºC
Flash point:92.9ºC
Index of Refraction:1.476
 
Specification:
Appearance:Beige to grey to brown crystalline powder
Assay:≥98.0%
Moisture:≤0.2%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 2-Methoxy-5-(trifluoromethyl)aniline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Amino-4-methoxybenzotrifluoride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Methoxy-5-(trifluoromethyl)aniline Use and application,2-Methoxy-5-(trifluoromethyl)aniline technical grade,usp/ep/jp grade.


Related News: Cases recorded in Thailand, Taiwan, Germany, Vietnam, Japan, France and the United States involved patients who had not been to China.2-fluoroadenosine manufacturer Cases recorded in Thailand, Taiwan, Germany, Vietnam, Japan, France and the United States involved patients who had not been to China.Ethyl Silicate 32 supplier It is delivered to hospitals and pharmacies until it reaches the patient.2,4-Difluorophenylboronic acid vendor Take penicillin industrial salt and vitamin C as examples. They are the two strategic varieties of chemical raw materials in China, and they are also representatives of severe overcapacity.The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.